M&A / Deals Biogen pens $1bn deal to buy immunology biotech RayThera PharmaphorumBiogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion.Immunology & InflammationRead full story pharminent June 18, 2026 (Last updated: June 18, 2026) Pharmaphorum Biogen has agreed its second takeover deal of 2026, an acquisition of immunology start-up RayThera valued at up to $1 billion. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Previous PostNext: LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
